Andreia joins from TFS Health Science, a global CRO, where she was the EVP HR, Talent Acquisition and Marketing & Communications.
2nd March 2022. Bionical Emas, a global Clinical Research Organisation (CRO) providing services to the pharmaceutical and biotech sectors, has appointed Andreia de Melo Cabral as its first Chief People Officer (CPO).
Andreia joins from TFS Health Science, a global CRO, where she was the EVP HR, Talent Acquisition and Marketing & Communications.
Andreia joins from TFS Health Science, a global CRO, where she was the EVP HR, Talent Acquisition and Marketing & Communications.
Andreia has a wide range of international experience, having held senior HR management positions in publicly listed and private equity owned companies, operating in the EU, Africa, Middle East, and the US.
Andreia will be leading the Bionical Emas People Strategy across the global business, reporting to CEO, Jonathan Waring-Hughes. She joins the Executive Leadership Team. Her primary goal will be to help shape and implement the Company’s values and an integrated company culture across the business in order to support its long-term sustainable growth and operational excellence.
Jonathan Waring-Hughes, Chief Executive Officer at Bionical Emas, said:
“With her considerable international and sector expertise and experience, Andreia has an important role as she focusses on several key global initiatives to support the next phase of our exciting development.
“Andreia’s appointment is the first of a number of senior appointments we will be making over the next few months as we strengthen the depth and experience of our senior team to support our ambitious international growth plans.”
Contact details
Bionical Emas Ltd
Katie Clayton, Head of Marketing +44 (0) 1462 416435
Meare Consulting
Adrian Duffield +44 (0) 7990 858548
adrian.duffield@meareconsulting.com
Note to Editors:
Bionical Emas is a Clinical Research Organisation (CRO) which combines Clinical Development, Early Access Program (EAP) and Clinical Trial Supply (CTS) services to deliver a unique, seamless approach to pioneering the way life-changing medicines are developed and accessed for patients around the world.
The Group deliver full clinical development services to global pharma and biotech companies. It’s integrated suite of services enables Bionical Emas to maximize access, collect data and generate evidence at every point along the drug development pathway.
Bionical Emas runs global programs, employs 200 people, and has offices in US, Europe, and Australia. It serves 10 of the top 25 pharma companies.
For more information on Bionical Emas, please visit www.bionicalemas.com.